ZGGS18 for Injection

BIOLOGICAL2 trials

Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions

Advanced Solid Tumor

Phase 1

Study of ZGGS18 in Patients With Advanced Solid Tumors

RecruitingNCT05584800

Suzhou Zelgen Biopharmaceuticals Co.,LtdAdvanced Solid Tumor

Start: 2022-11-15End: 2026-11-01Target: 222Updated: 2026-01-05

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

RecruitingNCT06938880

Suzhou Zelgen Biopharmaceuticals Co.,LtdAdvanced Solid Tumor

Start: 2025-05-20End: 2028-04-30Target: 60Updated: 2026-01-05

Related Papers

First-in-human study of ZGGS18, a dual specific antibody targeting VEGF and TGF-β, as monotherapy in patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-01